Belimumab in Lupus Nephritis: New Trial Results Arrive During an Exciting Time for Therapeutics

Am J Kidney Dis. 2021 Jun;77(6):984-987. doi: 10.1053/j.ajkd.2020.11.003. Epub 2020 Nov 20.

Authors

Nestor Oliva-Damaso¹, Andrew S Bomback²

Affiliations

¹ Division of Nephrology, Department of Medicine, Hospital Costa del Sol, Marbella, Malaga, Spain.
² Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. Electronic address: asb68@cumc.columbia.edu.

PMID: 33221369
DOI: 10.1053/j.ajkd.2020.11.003

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Clinical Trials, Phase III as Topic
Double-Blind Method
Humans
Lupus Nephritis / drug therapy*
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
belimumab